Image highlights the importance of patient-centered care, especially in cases of MDRO (Multi-Drug Resistant Organisms). A patient in a hospital gown is pictured, with text emphasizing the need to consider each individual's circumstances, such as being admitted abroad or having outbreak contact. A PCR test is also mentioned. #AMR #RaceAgainstResistance

 

The World is Running Out of Antibiotics.1 Help Fight Back with Fast PCR.

In the global race against antimicrobial resistance (AMR) and related healthcare-associated infections (HAIs), Cepheid provides diagnostic solutions that quickly and accurately identify pathogens and superbugs in around one hour* to enable the right isolation and treatment before it's too late.2,3

 

Join us in the race.

1.27 Million

Estimated deaths that bacterial AMR was directly responsible for in 20194

4.95 Million

Estimated deaths associated with bacterial AMR in 20194

$412 Billion

Estimated total expense to treat resistant bacterial infections per year by 20355

Protect Patients & Fight AMR with Fast PCR Results in ~1 Hour*

Fast and accurate PCR with Cepheid’s GeneXpert® System and Xpert® tests greatly improves time to result, allowing healthcare professionals to quickly identify, isolate and appropriately manage colonized or infected patients, helping prevent spread.2,3

 

PCR Impact: 

  • Improved bed & isolation management2
  • Reduced transmission & outbreaks2
  • Reduced duration of empiric therapy6
  • Reduced colonization & infection rates7
  • Reduced avoidable costs8
Cepheid's GeneXpert machine, featuring a cartridge loaded for molecular diagnostics.

Get Instant Access to our Thought Leadership Article

Click the link below to download our thought leadership article on antimicrobial resistance and why we should be concerned about carbapenemase-producing Enterobacterales. 

Speak to our experts today!

Let’s talk stewardship & outbreak prevention.

I would like to be part of the Cepheid Community and I understand and consent to receive information about products and services, invitations to virtual and in-person events such as workshops and webinars and educational content from Cepheid and similar information from Cepheid’s affiliates and representatives.

*required fields
Cepheid respects your privacy, and values the relationship with our customers, partners, and associates. Your personal data may be processed by Cepheid, its affiliates, representatives and other Danaher companies for business and marketing purposes. You can review Cepheid Privacy Policy online for additional information on your rights and how we use and share personal data we collect on our websites and other channels. Your consent to receiving Cepheid news can be withdrawn at any time. Building a relationship of trust is important to us and we will happily help with any questions on your personal data processing addressed to Privacy.officer@cepheid.com

 

Join Cepheid in the race against resistance.
Stop the spread.

 

IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.

* Turnaround times vary by test. See individual Product Inserts for specific turnaround times.

1. World Health Organization (WHO). July 2022 Report: Antimicrobial Resistance. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance?_ga=2.20730424.149613883.1682706550-
1577130351.1682706550
2. Corless C, et al. Impact of different carbapenemase-producing Enterobacterales screening strategies in a hospital setting. IPIP. 2020 May;3(2):100011.
3. Casari E, et al. Reducing rates of C. difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).
4. Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 399(10325):P629-655.
5. Global Leaders Group (GLG) on AMR. GLG report: Towards specific commitments and action in the response to antimicrobial resistance. https://www.amrleaders.org/resources/m/item/glg-report
6. Peppard W, et al. Implementation of polymerase chain reaction to rule out C. difficile infection is associated with reduced empiric antibiotic duration of therapy. Hosp Pharm. 2014 Jul;49(7):639-43.
7. Zhou M, et al. Active surveillance of carbapenemase-producing organisms (CPO) colonization with Xpert® Carba-R assay plus positive patient isolation proves to be effective in CPO containment.
Front Cell Infect Microbiol. 2019 May;14(9):162.
8. Birgand G, et al. Cost associated with implementation of a strict policy for controlling spread of highly resistant microorganisms in France. BMJ Open. 2016 Jan;6:e009029.

About Cepheid

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid's broad test portfolio spans respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company's solutions deliver actionable results where they are needed most from central laboratories and hospitals to near patient settings.

For more information, visit www.cepheid.com

904 Caribbean Drive, Sunnyvale, CA 94089

©2025 Cepheid. All Rights Reserved.